Predictive Value of HER2 Serum Levels in Patients Treated with Lapatinib or Trastuzumab -- a Translational Project in the Neoadjuvant GeparQuinto Trial

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Aug 16

PMID 22892393

Citations 19

Authors

I Witzel

S Loibl

G von Minckwitz

H Eidtmann

T Fehm

F Khandan

S Schmatloch

M Hauschild

J Bischoff

P A Fasching

C Mau

C Schem

B Rack

I Meinhold-Heerlein

C Liedtke

T Karn

J Huober

C Zu Eulenburg

Y Issa-Nummer

M Untch

V Muller

Affiliations

Soon will be listed here.

Abstract

Background: We were able to demonstrate a predictive value of serum HER2 (sHER2) in patients receiving trastuzumab in the neoadjuvant GeparQuattro trial. However, the role of sHER2 in patients receiving neoadjuvant therapy (NT) with lapatinib is still unclear.

Methods: The neoadjuvant GeparQuinto trial compared trastuzumab vs lapatinib in addition to chemotherapy in HER2-positive primary breast cancer patients. The sHER2 levels were measured by enzyme-linked immunosorbant assay in 210 patients, of whom 109 (52%) patients received trastuzumab and 101 (48%) lapatinib at three different time points.

Results: Twenty-two percent of patients had elevated baseline sHER2 levels (>15 ng ml⁻¹). A decrease of sHER2 levels (>20%) in the trastuzumab and lapatinib-treated group during NT was seen in 44% and 24% of the patients, an increase of sHER2 levels (>20%) was seen in 6% and 41% of patients, respectively. Higher pre-chemotherapy sHER2 levels were associated with higher pathological complete remission (pCR) rates in the entire study cohort (OR 1.8, 95% CI 1.02-3.2, P=0.043). A decline of sHER2 levels (>20%) during NT was a predictor for pCR in the lapatinib-treated patient group (OR: 11.7, 95% CI 1.3-110, P=0.031).

Conclusion: Results of this study demonstrate that sHER2 levels change differently during NT depending on the anti-HER2 treatment strategy. Elevated baseline sHER2 levels (>15 ng ml⁻¹) and a decrease of sHER2 levels (>20%) early after therapy initiation are both relevant criteria to predict response to lapatinib-based treatment.

Citing Articles

Current status and future perspectives in HER2 positive advanced gastric cancer.

Roviello G, Catalano M, Iannone L, Marano L, Brugia M, Rossi G Clin Transl Oncol. 2022; 24(6):981-996.

PMID: 35091998 DOI: 10.1007/s12094-021-02760-0.

Serum HER2 levels predict treatment efficacy and prognosis in patients with HER2-positive breast cancer undergoing neoadjuvant treatment.

Zuo W, He M, Zheng H, Liu Y, Liu X, Jiang Y Gland Surg. 2021; 10(4):1300-1314.

PMID: 33968682 PMC: 8102211. DOI: 10.21037/gs-20-802.

Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?.

Roviello G, Aprile G, DAngelo A, Iannone L, Roviello F, Polom K Gastric Cancer. 2021; 24(4):765-779.

PMID: 33742317 DOI: 10.1007/s10120-021-01182-9.

A Phenomic Perspective on Factors Influencing Breast Cancer Treatment: Integrating Aging and Lifestyle in Blood and Tissue Biomarker Profiling.

Arana Echarri A, Beresford M, Campbell J, Jones R, Butler R, Gollob K Front Immunol. 2021; 11:616188.

PMID: 33597950 PMC: 7882710. DOI: 10.3389/fimmu.2020.616188.

HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes.

Hart V, Gautrey H, Kirby J, Tyson-Capper A Oncotarget. 2020; 11(46):4338-4357.

PMID: 33245725 PMC: 7679030. DOI: 10.18632/oncotarget.27789.

References

Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J . Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007; 99(8):628-38. DOI: 10.1093/jnci/djk134. View

Baselga J . Is circulating HER-2 more than just a tumor marker?. Clin Cancer Res. 2001; 7(9):2605-7. View

Finn R, Gagnon R, Di Leo A, Press M, Arbushites M, Koehler M . Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol. 2009; 27(33):5552-8. DOI: 10.1200/JCO.2008.21.1763. View

Codony-Servat J, Albanell J, Lopez-Talavera J, Arribas J, Baselga J . Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 1999; 59(6):1196-201. View

Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Del Barco S, Martin-Castillo B, Menendez J . Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth. J Cell Physiol. 2010; 226(1):52-7. DOI: 10.1002/jcp.22333. View

Untch M, Fasching P, Konecny G, Hasmuller S, Lebeau A, Kreienberg R . Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011; 29(25):3351-7. DOI: 10.1200/JCO.2010.31.4930. View

Hudelist G, Kostler W, Attems J, Czerwenka K, Muller R, Manavi M . Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer. 2003; 89(6):983-91. PMC: 2376939. DOI: 10.1038/sj.bjc.6601160. View

Gianni L, Pienkowski T, Im Y, Roman L, Tseng L, Liu M . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2011; 13(1):25-32. DOI: 10.1016/S1470-2045(11)70336-9. View

Lipton A, Ali S, Leitzel K, Demers L, Chinchilli V, Engle L . Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002; 20(6):1467-72. DOI: 10.1200/JCO.2002.20.6.1467. View

10.

Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C . Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2012; 379(9816):633-40. PMC: 5705192. DOI: 10.1016/S0140-6736(11)61847-3. View

11.

Esteva F, Valero V, Booser D, Guerra L, Murray J, Pusztai L . Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(7):1800-8. DOI: 10.1200/JCO.2002.07.058. View

12.

Kostler W, Steger G, Soleiman A, Schwab B, Singer C, Tomek S . Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer. Anticancer Res. 2004; 24(2C):1127-30. View

13.

Untch M, Rezai M, Loibl S, Fasching P, Huober J, Tesch H . Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010; 28(12):2024-31. DOI: 10.1200/JCO.2009.23.8451. View

14.

Ali S, Carney W, Esteva F, Fornier M, Harris L, Kostler W . Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer. 2008; 113(6):1294-301. DOI: 10.1002/cncr.23689. View

15.

Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J . Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012; 13(2):135-44. DOI: 10.1016/S1470-2045(11)70397-7. View

16.

Molina M, Saez R, Ramsey E, Garcia-Barchino M, Rojo F, Evans A . NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res. 2002; 8(2):347-53. View

17.

Lipton A, Leitzel K, Ali S, Carney W, Platek G, Steplewski K . Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy. Cancer. 2011; 117(21):5013-20. DOI: 10.1002/cncr.26101. View

18.

Buzdar A, Ibrahim N, Francis D, Booser D, Thomas E, Theriault R . Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23(16):3676-85. DOI: 10.1200/JCO.2005.07.032. View

19.

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

20.

Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva F . Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer. 2006; 109(3):496-501. DOI: 10.1002/cncr.22418. View